Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas | Zendy

Alessandra Fusco | Zendy; Ginette Gunz | Zendy; P Jaquet | Zendy; Henry Dufour | Zendy; Anne Laure Germanetti | Zendy; Michael D. Culler | Zendy; Anne Barlier | Zendy; Alexandru Saveanu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas

Author(s) -

Alessandra Fusco,

Ginette Gunz,

P Jaquet,

Henry Dufour,

Anne Laure Germanetti,

Michael D. Culler,

Anne Barlier,

Alexandru Saveanu

Publication year - 2008

Publication title -

european journal of endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 148

eISSN - 1479-683X

pISSN - 0804-4643

DOI - 10.1530/eje-07-0806

Subject(s) - cabergoline , prolactinoma , endocrinology , medicine , somatostatin , somatostatin receptor 2 , prolactin , agonist , dopamine agonist , dopamine , biology , somatostatin receptor , receptor , chemistry , dopaminergic , hormone

Ten percent of patients with prolactinoma fail to respond with normalization of prolactin (PRL) and tumor shrinkage under dopamine agonist (DA) therapy. The resistance to treatment is linked to a loss of dopamine receptor 2 (D2DR). Prolactinomas express somatostatin (SST) receptor subtypes, SSTR1, 2, and 5. The aim of this study was to determine whether different SST compounds could overcome the resistance to DA in prolactinomas.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research